|
Molecular characterization and subsequent treatments after encorafenib-cetuximab +/- binimetinib in BRAF V600E-mutated colorectal cancer. |
|
|
Speakers' Bureau - Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Travel, Accommodations, Expenses - Amgen; Merck; Sanofi |
|
|
Honoraria - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen |
|
|
Stock and Other Ownership Interests - Reveal Genomics |
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Incyte (Inst); Merck (Inst); Roche (Inst) |
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc |
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource |
|
|
No Relationships to Disclose |